Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
Fei Wang,1 Justine Surh,1 Manmeet Kaur21University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, 2Joslin Diabetes Center Affiliate, Hospital of Central Connecticut, New Britain, CT, USABackground: Insulin degludec (IDeg) is a neutral, ultralong-acting new generation bas...
Guardado en:
Autores principales: | Wang F, Surh J, Kaur M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0edc798221ed4ca4b84db80b9a1d4bb9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
por: Thuillier P, et al.
Publicado: (2015) -
Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
por: Sinha B, et al.
Publicado: (2014) -
Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
por: Berlie H, et al.
Publicado: (2012) -
Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe S, et al.
Publicado: (2011) -
Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis
por: Kostev K, et al.
Publicado: (2015)